Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1965
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1973 1
1974 2
1976 2
1977 1
1978 2
1979 3
1980 2
1981 1
1982 5
1983 2
1984 6
1985 7
1986 8
1987 3
1988 5
1989 9
1990 10
1991 10
1992 11
1993 18
1994 20
1995 11
1996 22
1997 21
1998 14
1999 22
2000 28
2001 20
2002 18
2003 34
2004 30
2005 15
2006 21
2007 24
2008 21
2009 26
2010 34
2011 36
2012 37
2013 39
2014 46
2015 51
2016 48
2017 68
2018 66
2019 54
2020 75
2021 53
2022 69
2023 77
2024 59
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,115 results

Results by year

Filters applied: . Clear all
Page 1
Hepatic Lymphoma Diagnosis.
Choi WT, Gill RM. Choi WT, et al. Surg Pathol Clin. 2018 Jun;11(2):389-402. doi: 10.1016/j.path.2018.02.003. Epub 2018 Mar 21. Surg Pathol Clin. 2018. PMID: 29751882 Review.
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. Hepatopathologists must be familiar with the full spectrum of hematopoietic disorders involving the liver and be prepared to exclude benign mi …
Systemic hematopoietic disorders may present on liver biopsy, and rare cases of primary hepatic lymphoma (PHL) may be encountered. He …
Glofitamab CD20-TCB bispecific antibody.
Minson A, Dickinson M. Minson A, et al. Leuk Lymphoma. 2021 Dec;62(13):3098-3108. doi: 10.1080/10428194.2021.1953016. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263696 Review.
Bispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignancies and act by simultaneously targeting antigens on T-cells and malignant cells to effect tumor cell death. Glofitamab is a novel full-length …
Bispecific T-cell recruiting antibodies are emerging as a potent immunotherapeutic class in the treatment of B-cell malignanci …
Blinatumomab: a historical perspective.
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Nagorsen D, et al. Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the individual disease, monoclonal antibodies, irradiation and/or hematopoietic stem cell transplantation are added. ...Here, we review how blinatumo …
For decades, chemotherapy has been the backbone for the treatment of patients with B cell malignancies. Depending on the indiv …
Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K, Sheikh T, Aggarwal N. Davis K, et al. Semin Diagn Pathol. 2023 May;40(3):202-215. doi: 10.1053/j.semdp.2023.04.003. Epub 2023 Apr 9. Semin Diagn Pathol. 2023. PMID: 37120350 Review.
Tremendous strides have been made in the molecular and cytogenetic classification of acute lymphoblastic leukemia based on gene expression profiling data, leading to an expansion of entities in the recent International Consensus Classification (ICC) of myeloid neoplasms an …
Tremendous strides have been made in the molecular and cytogenetic classification of acute lymphoblastic leukemia based on gene expre …
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.
Teachey DT, Pui CH. Teachey DT, et al. Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2. Lancet Oncol. 2019. PMID: 30842058 Free PMC article. Review.
Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Finally, patients with B-cell ALL are more amendable to available targeted therapies, such as Philadelphia chromosome-positive and …
Third, T-cell ALL blasts are generally more resistant to conventional chemotherapeutic drugs than are B-cell ALL blasts. Final …
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD, O'Brien MM. Rubinstein JD, et al. Front Immunol. 2023 Aug 3;14:1237738. doi: 10.3389/fimmu.2023.1237738. eCollection 2023. Front Immunol. 2023. PMID: 37600823 Free PMC article. Review.
InO has shown significant activity in relapsed and refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in both single agent and combination chemotherapy regimens in adult and pediatric trials. ...In the relapsed/refractory (R/R) setting, the pl …
InO has shown significant activity in relapsed and refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) i …
Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS, Selemon H, Elton SM, Parinandi NL. Elton TS, et al. Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adaptors for the miRNA-induced silencing complex to inhibit gene expression by targeting mRNAs for translational repression and/or cleavage. miR- …
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adapt …
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.
Alderuccio JP, Lossos IS. Alderuccio JP, et al. Leuk Lymphoma. 2022 Feb;63(2):279-290. doi: 10.1080/10428194.2021.1984452. Epub 2021 Sep 29. Leuk Lymphoma. 2022. PMID: 34586000 Review.
Over the last decade, growing data demonstrated frequent NOTCH2 mutations in splenic marginal zone lymphoma (SMZL) underscoring its critical role in the pathogenesis of this disease. Moreover, NOTCH2 specificity across studies supports the rationale to assess its value as …
Over the last decade, growing data demonstrated frequent NOTCH2 mutations in splenic marginal zone lymphoma (SMZL) underscoring its c …
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.
Tees MT, Flinn IW. Tees MT, et al. Expert Rev Hematol. 2017 Feb;10(2):137-146. doi: 10.1080/17474086.2017.1270203. Epub 2016 Dec 26. Expert Rev Hematol. 2017. PMID: 27936980 Review.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. ...
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more …
1,115 results